Walleye Capital
GPCR icon

Walleye Capital’s Structure Therapeutics GPCR Stock Holding History

Walleye Capital’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-21,360
Closed -$1.03M – 4897
2026
Q1 		$1.03M Buy
21,360
+21,358
+1,067,900% +$1.46M ﹤0.01% 2049
2025
Q4 		$139 Sell
2
-4,488
-100% -$183K ﹤0.01% 4424
2025
Q3 		$126K Sell
4,490
-34,183
-88% -$681K ﹤0.01% 3593
2025
Q2 		$802K Buy
+38,673
New +$850K ﹤0.01% 2231
2025
Q1 		– Sell
-11,656
Closed -$316K – 4573
2024
Q4 		$316K Buy
+11,656
New +$414K ﹤0.01% 3379
2024
Q3 		– Sell
-400
Closed -$15.7K – 5495
2024
Q2 		$15.7K Sell
400
-93,394
-100% -$3.83M ﹤0.01% 5159
2024
Q1 		$4.02M Buy
+93,794
New +$3.96M 0.01% 1456

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Walleye Capital's GPCR Position: Q2 2026 in Review

Walleye Capital sold out of Structure Therapeutics (GPCR) in Q2 2026, closing a stake of 21,360 shares — an estimated $1.03M sold.

Walleye Capital first reported a position in GPCR in Q1 2024 and held it in 7 quarters. The position peaked at $4.02M in Q1 2024. 191 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Walleye Capital reported no remaining Structure Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Walleye Capital sold 21,360 Structure Therapeutics shares in Q2 2026, an estimated $1.03M.
  • Walleye Capital first reported a position in Structure Therapeutics in Q1 2024 and held it in 7 quarters.
  • Walleye Capital's Structure Therapeutics position peaked at $4.02M in Q1 2024.
  • 191 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.